Anti-ERCC1 CE/IVD for IHC - Pulmonary pathology

Anti-ERCC1 CE/IVD for IHC - Pulmonary pathology

In pulmonary pathology, ERCC1 has been extensively studied in non-small cell lung cancer (NSCLC) as a DNA repair protein involved in the cellular response to platinum-induced DNA damage. Research has evaluated ERCC1 expression in tumor tissues using immunohistochemistry (IHC) and molecular approaches. Reported associations between ERCC1 expression levels and clinical outcomes, including response to platinum-based chemotherapy, have been inconsistent across studies, largely due to differences in assay design, antibody specificity, scoring methodologies, and tumor heterogeneity.

Biological Significance of ERCC1

  • Essential component of the nucleotide excision repair (NER) pathway involved in DNA damage repair.
  • Forms a functional endonuclease complex with XPF (ERCC1–XPF).
  • Participates in the 5’ incision step during repair of bulky DNA lesions.
  • Contributes to cellular repair of genotoxic stress, including platinum-induced DNA crosslinks.
  • Plays a role in maintaining genomic stability in normal and malignant cells.

Investigational Utility of ERCC1 in Pulmonary Pathology

  • Studied in NSCLC in the context of DNA repair capacity and response to platinum-based chemotherapy.
  • Evaluated in translational and clinical research using IHC and molecular techniques.
  • Reported associations between ERCC1 expression and treatment outcomes have been variable across studies.
  • Interpretation is affected by methodological variability, including antibody specificity and lack of full assay standardization.
  • Current evidence does not support ERCC1 as a fully standardized or universally validated predictive biomarker in clinical practice.

Key Features of Anti-ERCC1 CE/IVD Antibodies for IHC

  • Optimized for detection of ERCC1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue specimens.
  • Applicable to pulmonary and pleural samples within standardized histopathology workflows.
  • Supports visualization of ERCC1 expression in the context of preserved tissue architecture.
  • Intended for use in regulated diagnostic and/or research settings, depending on local regulatory frameworks.
  • Designed to support reliable IHC performance when used according to validated laboratory protocols.

 

Endometrial carcinoma section
Tonsil section

 

Search result : 3 product found

Refine your search :

RUO
CE/IVD
NEW
  • Unconjugated 3
  • human 3
  • mouse 3
  • Primary antibody
  • IHC 3
  • IHC568 3
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT